Previous close | 3.9900 |
Open | 4.0000 |
Bid | 3.9800 x N/A |
Ask | 4.0300 x N/A |
Day's range | 3.9900 - 4.0000 |
52-week range | 0.8000 - 5.2300 |
Volume | |
Avg. volume | 29,850 |
Market cap | 86.002M |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0400 |
Earnings date | 07 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.02 |
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has completed enrollment, randomization and dosing of the last patient, in its Phase 2 trial that is evaluating the efficacy and safety of EP-104 for the treatment of osteoarthritis ("OA") of the knee.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Paul Brennan to the role of Chief Business Officer ("CBO").